HealthDay News — A once-promising investigational vaccine against herpes viruses showed only 20% efficacy against herpes genital disease in a large clinical trial designed to mimic the general ...

Background: Complement independent neutralizing antibody assays (CINA) have been used in seroepidemiologic studies and in diagnostic laboratories to distinguish between antibodies to herpes simplex ...

The rise of sexually transmitted infections (STIs) continues to pose threats. The prevalence of one uncurable STI in particular – genital herpes simplex virus (HSV) type 1 and 2 – is at a global high, ...

WOBURN, Mass. and OXFORD, England, July 8, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced ...

– Late-breaking oral presentation highlights interim Phase 1b data reported earlier this year for two cohorts in participants with recurrent genital herpes – – Statistically significant reductions in ...

Assembly Biosciences Inc. has selected development candidate ABI-5366 to progress to IND-enabling studies from its long-acting herpes simplex virus type 2 (HSV-2) helicase inhibitor program for ...

Background: Several commercial type-specific sérologie tests are available for herpes simplex virus type 2 (HSV-2). Poor specificity of some tests has been reported on samples from sub-Saharan Africa.

Eurocine Vaccines AB has reported findings from preclinical studies evaluating its mRNA and protein technology platforms for its therapeutic herpes simplex virus type 2 (HSV-2) vaccine candidates.

– ABI-5366 is currently being evaluated in ongoing Phase 1b clinical trial with interim proof-of-concept data expected in fall 2025 – SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ...